Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL133924 | 0.92 | AKT1 (0.41) | ALDH1A1AKT1MAPTMEN1KMT2A | |
| SCHEMBL133925 | 0.92 | AKT1 (0.41) | ALDH1A1AKT1MAPTMEN1KMT2A | |
| SCHEMBL1931541 | 0.90 | AKT1 (0.40) | ALDH1A1AKT1MAPTMEN1KMT2A | |
| SCHEMBL1931543 | 0.90 | AKT1 (0.40) | ALDH1A1AKT1MAPTMEN1KMT2A | |
| Propionic Acid SCHEMBL1525114 | 0.82 | CES2 (0.42) | ALDH1A1AKT1MAPTRECQLLMNA | |
| Propionic Acid SCHEMBL1525115 | 0.82 | CES2 (0.42) | ALDH1A1AKT1MAPTRECQLLMNA | |
| SCHEMBL6415855 | 0.81 | TSHR (0.50) | ALDH1A1AKT1MAPTRECQLRAB9A | |
| SCHEMBL11221544 | 0.81 | TDP1 (0.43) | ALDH1A1AKT1MAPTRECQLMTNR1A | |
| SCHEMBL11221549 | 0.81 | TDP1 (0.43) | ALDH1A1AKT1MAPTRECQLMTNR1A | |
| SCHEMBL57798 | 0.77 | AKT1 (0.46) | ALDH1A1AKT1MAPTRECQLMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210106687-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | LAUREN SCIENCES LLC | 2021-04-15 | — | — | US | disclosed |
| EP-3532024-B1 | COSMETIC USE AND METHOD FOR IMPROVING PHYSIOLOGICAL FUNCTIONS OF THE SKIN BY INCREASING THE EXPRESSION OF UBIAD1 | ISP INVESTMENTS LLC (US) | 2021-02-24 | — | — | EP | disclosed |
| US-20190269596-A1 | COSMETIC USE AND METHOD FOR IMPROVING PHYSIOLOGICAL FUNCTIONS OF THE SKIN BY INCREASING THE EXPRESSION OF UBIAD1 | ISP INVESTMENTS LLC (US) | 2019-09-05 | — | — | US | disclosed |
| EP-3532024-A1 | COSMETIC USE AND METHOD FOR IMPROVING PHYSIOLOGICAL FUNCTIONS OF THE SKIN BY INCREASING THE EXPRESSION OF UBIAD1 | ISP Investments LLC (US) | 2019-09-04 | — | — | EP | disclosed |
| US-20190076533-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | LAUREN SCIENCES LLC (US) | 2019-03-14 | — | — | US | disclosed |
| EP-2252304-B1 | PLATINUM AGGREGATES AND PROCESS FOR PRODUCING THE SAME | TRANSAVE INC (US) | 2018-07-18 | — | — | EP | disclosed |
| WO-2018078079-A1 | COSMETIC USE AND METHOD FOR IMPROVING PHYSIOLOGICAL FUNCTIONS OF THE SKIN BY INCREASING THE EXPRESSION OF UBIAD1 | ISP INVESTMENTS LLC (US) | 2018-05-03 | — | — | WO | disclosed |
| US-20160263030-A1 | PLATINUM AGGREGATES AND PROCESS FOR PRODUCING THE SAME | INSMED INC (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160166608-A1 | METHODS OF TREATING CANCER WITH HIGH POTENCY LIPID-BASED PLATINUM COMPOUND FORMULATIONS ADMINISTERED INTRAPERITONEALLY | INSMED INC (US) | 2016-06-16 | — | — | US | disclosed |
| US-9186322-B2 | Platinum aggregates and process for producing the same | INSMED INCORPORATED (US) | 2015-11-17 | — | — | US | disclosed |
| US-20120070490-A1 | ANTI-TRYPANOSOMAL PEPTIDES AND USES THEREOF | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| EP-2252304-A2 | PLATINUM AGGREGATES AND PROCESS FOR PRODUCING THE SAME | Transave, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009100330-A2 | PLATINUM AGGREGATES AND PROCESS FOR PRODUCING THE SAME | TRANSAVE, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090130193-A1 | Methods of Treating Cancer with High Potency Lipid-Based Platinum Compound Formulations Administered Intraperitoneally | TRANSAVE, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090130194-A1 | Methods of Treating Cancer with High Potency Lipid-Based Platinum Compound Formulations Administered Intravenously | TRANSAVE, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20080187578-A1 | Complex of lipid and platimun compound | TRANSAVE, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| EP-1545459-A4 | PLATINUM AGGREGATES AND PROCESS FOR PRODUCING THE SAME | TRANSAVE INC (US) | 2007-08-22 | — | — | EP | disclosed |
| EP-1545459-A2 | PLATINUM AGGREGATES AND PROCESS FOR PRODUCING THE SAME | Transave, Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004054499-A2 | PLATINUM AGGREGATES AND PROCESS FOR PRODUCING THE SAME | TRANSAVE, INC. (US) | 2004-07-01 | — | — | WO | disclosed |
| US-20040101553-A1 | Platinum aggregates and process for producing the same | TRANSAVE, INC. | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210106687-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | LGALS1, BOLA2; BOLA2B, LGALS2 | ALDH1A1 344/4885AKT1 4089/4885MAPT 856/4885 |
| US-20090130193-A1 | Methods of Treating Cancer with High Potency Lipid-Based Platinum Compound Formulations Administered Intraperitoneally | SGMS2, SGMS1, LPCAT3 | ALDH1A1 1280/4885AKT1 1560/4885MAPT 4613/4885 |
| US-20160166608-A1 | METHODS OF TREATING CANCER WITH HIGH POTENCY LIPID-BASED PLATINUM COMPOUND FORMULATIONS ADMINISTERED INTRAPERITONEALLY | SGMS2, SGMS1, LPCAT3 | ALDH1A1 1280/4885AKT1 1560/4885MAPT 4613/4885 |
| US-20090130194-A1 | Methods of Treating Cancer with High Potency Lipid-Based Platinum Compound Formulations Administered Intravenously | SGMS1, SGMS2, PHOSPHO1 | ALDH1A1 2059/4885AKT1 2187/4885MAPT 4172/4885 |
| US-20190076533-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | LGALS1, BOLA2; BOLA2B, LGALS2 | ALDH1A1 408/4885AKT1 4321/4885MAPT 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.